Johnson & Johnson to Buy Ollin Biosciences for Up to $3.3 Billion in Eye Drug Deal

Johnson & Johnson has agreed to buy Ollin Biosciences for $2.2 billion upfront plus up to about $1.125 billion in milestones, adding OLN324, a Phase 3 eye drug for wet AMD and diabetic macular edema, while Blackstone Life Sciences funds the drug's Phase 3 programme with $750 million.

NGN Market

Written by NGN Market

·3 min read
Johnson & Johnson to Buy Ollin Biosciences for Up to $3.3 Billion in Eye Drug Deal

Johnson & Johnson has scale in eye care but little of it in prescription drugs: its vision business rests largely on contact lenses, devices and surgical equipment, and Reuters noted its limited footprint in eye disease therapies despite that presence. Ollin, founded in 2023, gives it a late-stage medicine to build around. OLN324 uses a small protein format designed for high Ang2 potency and tighter control of retinal fluid, and it originated at Shanghai-based Innovent Biologics before Ollin took it into global development. Four Phase 3 studies are under way, two in wet AMD and two in diabetic macular edema.

A Purchase With the Trial Bill Paid by Someone Else

The financing structure is as notable as the asset. Johnson & Johnson pays $2.2 billion in cash at closing, yet the cost of proving OLN324 in Phase 3 sits with Blackstone Life Sciences, which will pay $750 million over multiple years to fully fund the programme and take milestones and royalties if the drug succeeds. That arrangement caps Johnson & Johnson's exposure at the upfront price plus contingent milestones while the most uncertain spending, the late-stage trials, is carried externally. The milestone cap of about $1.125 billion also corrects the early reporting of the deal: Sunday reports put the total at up to $3.4 billion, while the confirmed terms land closer to $3.3 billion.

The Bar Is a Blockbuster Already on the Market

OLN324 targets the same two proteins as Roche's Vabysmo, which has grown into a blockbuster since its 2022 approval by taking share from older therapies. That sets both the opportunity and the risk. A drug that controls retinal fluid for longer between injections would have a clear commercial claim in a market this large, but Phase 1b data are a thin basis for assuming superiority over an entrenched competitor, and the Phase 3 readouts will decide whether the $2.2 billion bought a franchise or an expensive second entrant. Johnson & Johnson is effectively paying for the option, with Blackstone funding the experiment that prices it.

Tags:Stocks

Advertisement

Advertisement